image credit- shutterstock
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, and Sensible Biotechnologies, a pioneer in cell-based design and manufacturing of mRNA therapeutics, have signed a Memorandum of Understanding (MoU).
The two companies will jointly advance the industrialisation and scale-up of Sensible’s first-in-class cell-based platform for the design, optimisation, and manufacturing of high-quality mRNA. The collaboration aims to enable clinical-grade production of cell-based mRNA by 2026 and unlock the next generation of mRNA medicines.
As part of the agreement, Sartorius Stedim Biotech has already provided significant support through advanced equipment and consumables. The partnership will extend to process development, closed-system facility design, and technical support to rapidly establish Sensible’s GMP-compliant mRNA production capabilities. These activities will enable Sensible to expand production from Slovakia to the US, UK, and broader Europe.
The MoU also outlines potential areas for deeper collaboration, reflecting both companies’ commitment to enabling scalable, high-quality mRNA manufacturing worldwide.
